The board of immunology biotech Acelyrin has rejected the buyout offer from Tang Capital’s shell company Concentra Biosciences, clearing up any doubt about its … ...
Acelyrin has declined a surprise offer from Concentra Biosciences, and is instead pushing ahead with plans to merge with immune-mediated disease specialist Alumis. Los Angeles-based Acelyrin ...
Concentra Group Holdings Parent Inc. earnings at a glance (GAAP) : -Earnings: $21.51 Mln. vs. $27.84 Mln. last year. -EPS: $0.17 vs. $0.27 last year. -Revenue: $465.04 Mln vs. $440.74 Mln last year.
Reports Q4 revenue $465M, consensus $465M. “Concentra (CON) had a successful 2024 – a year marked by change with our IPO and separation from Select Medical. We made significant progress on key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback